New process for the synthesis of ivabradine, also known as 3-{ 3-[ { [(7S)-3,4-dimethoxybicyclo[ 4.2.0]octa-1 ,3,5-trien-7-yl]methyl } (methyl)amino]propyl} -7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, and addition salts thereof with a pharmaceutically acceptable acid
Disclosed is a process for preparing an ivabradine compound represented by general formula (I) also known as 3-{ 3-[ { [(7S)-3,4-dimethoxybicyclo[ 4.2.0]octa-1 ,3,5-trien-7-yl]methyl } (methyl)amino]propyl} -7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one. The process involves subjecting a compound of general formula (VI), which is disclosed in the specification, to a thiol in organic solvent to form a hemithioacetal. The hemithioacetal then undergoes a cyclisation reaction followed by a reduction step to produce the ivabradine compound of general formula (I).
